抗神经退行性疾病复方药物研究进展

doi:10.19803/j.1672-8629.20240277

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (9): 967-972.
DOI: 10.19803/j.1672-8629.20240277

• 复方与联合用药安全性评价专栏（二） • 上一篇下一篇

抗神经退行性疾病复方药物研究进展

徐泽澳^1,2, 江海燕², 范潇予², 李万芳^2,3, 包捷^2,3, 徐成^1#, 靳洪涛^2,3,4,*

¹沈阳药科大学生命科学与生物制药学院辽宁沈阳 110016;
²中国医学科学院北京协和医学院药物研究所新药安全评价研究中心,北京 100050;
³北京协和建昊医药技术开发有限责任公司,北京100176;
⁴国家药品监督管理局创新药物安全研究与评价重点实验室,北京 102206

收稿日期:2024-04-28 出版日期:2024-09-15 发布日期:2024-09-14
通讯作者: ^*靳洪涛,男,研究员·博导,药物毒理学。E-mail：jinhongtao@imm.ac.cn。 ^#为共同通信作者。
作者简介:徐泽澳,男,在读硕士,药理学。
基金资助:
国家自然科学基金资助项目（82074104）; 中国毒理学会临床毒理学转化研究课题（CST2021CT101）

Research progress in compound drugs for anti-neurodegenerative diseases

XU Zeao^1,2, JIANG Haiyan², FAN Xiaoyu², LI Wanfang^2,3, BAO Jie^2,3, XU Cheng^1#, JIN Hongtao^2,3,4,*

¹College of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang Liaoning 110016, China;
²New Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China;
³Beijing Union-Genius Pharmaceutical Technology Development Co., Ltd., Beijing 100176, China;
⁴NMPA Key Laboratory for Safety Research and Evaluation of Innovative Drug, Beijing 102206, China

Received:2024-04-28 Online:2024-09-15 Published:2024-09-14

摘要/Abstract

摘要： 目的综述抗神经退行性疾病复方药物开发原则,总结近年来针对神经退行性疾病开发的复方药物,介绍复方药物作用机制,为神经退行性疾病复方药物研发提供参考。方法通过检索国内外相关文献及数据库,对已开发或进入临床试验的复方药物及药物作用机制进行整理、分析和归纳。结果目前已在受体抑制药、单克隆抗体药、神经保护药、炎症抑制药等药物的研究有显著进展,这些药物通过多靶点作用,能够改善记忆和认知能力,明显延缓疾病的发展进程,为提高神经退行性疾病患者的生活质量、改善患者运动状态带来了新的希望。结论抗神经退行性疾病复方药物具有显著治疗优势,但由于发病机制复杂、病程无法逆转等问题在开发过程中仍面临诸多挑战,生物信息技术、精准医疗和纳米递释系统等新兴技术的结合可为复方药物开发提供强大的技术支撑和创新动力。

关键词: 神经退行性疾病, 复方药物, 炎症抑制, 神经保护, 多靶点, 纳米递释系统

Abstract: Objective To review the principles of development of compound drugs for neurodegenerative diseases, summarize the related compound drugs developed in recent years and introduce their mechanism of action. Methods By searching relevant literature and databases at home and abroad, compound drugs and that have been developed or entered clinical trials and their mechanisms of action are summarized and analyzed. Results Significant progress has been made in the research on receptor suppressants, monoclonal antibody drugs, neuroprotective drugs and inflammatory suppressants. These drugs can improve memory and cognitive abilities through multi-target effects, significantly delay the progression of the disease, and bring new hopes for improving the quality of life of patients with neurodegenerative diseases and enhancing their motor function. Conclusion Compound drugs for treating neurodegenerative diseases have significant therapeutic advantages, but due to the complicated pathogenesis and irreversible course of disease, the development of these drugs remains challenging. The combination of emerging technologies such as bioinformatics technology, precision medicine, and nanodelivery systems can provide strong technical support and impetus of innovation for the development of compound drugs.

Key words: neurodegenerative diseases, compound drugs, inflammation inhibition, neuroprotection, multi-target, nanodelivery system

中图分类号:

R916
R971

徐泽澳, 江海燕, 范潇予, 李万芳, 包捷, 徐成, 靳洪涛. 抗神经退行性疾病复方药物研究进展[J]. 中国药物警戒, 2024, 21(9): 967-972.

XU Zeao, JIANG Haiyan, FAN Xiaoyu, LI Wanfang, BAO Jie, XU Cheng, JIN Hongtao. Research progress in compound drugs for anti-neurodegenerative diseases[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 967-972.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240277

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I9/967

参考文献

[1] REN R, QI J, LIN S, et al.The China Alzheimer report 2022[J]. Gen Psychiatr, 2022, 35(1): e100751.
[2] TYSNES OB, STORSTEIN A.Epidemiology of Parkinson’s disease[J]. J Neural Transm (Vienna), 2017, 124(8): 901-905.
[3] CHEN L, ZHANG B, CHEN R, et al.Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China[J]. J Neurol Neurosurg Psychiatry, 2015, 86(10): 1075-1081.
[4] TELEANU DM, NICULESCU AG, LUNGU II, et al.An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases[J]. Int J Mol Sci, 2022, 23(11): 5938.
[5] LU JM, LI ZY, GITLER DA, et al.Small molecule targeting strategies for“undruggable”targets in neurodegenerative diseases[J]. Science Bulletin, 2023, 68(16): 1715-1718.
[6] KHALAF K, TORNESE P, COCCO A, et al.Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases[J]. Translational Neurodegeneration, 2022, 11(1): 33.
[7] GENG WQ, YU Y, ZHONG YQ.Research progress on nanodrug delivery systems for the treatment of neurodegenerative diseases[J]. Herald of Medicine(医学导报), 2016, 35(1): 66-70.
[8] CAO Y, JIANG C.Progress in the research of brain-targeted nanomedicine delivery systems[J]. Basic ＆ Clinical Medicine(基础医学与临床), 2022, 42(1): 2-14.
[9] XU F, WU Y, YANG Q, et al.Engineered extracellular vesicles with SHP2 high expression promote mitophagy for Alzheimer’s disease treatment[J]. Adv Mater, 2022, 34(49): e2207107.
[10] YANG D, ZHANG W, ZHANG H, et al.Progress, opportunity, and perspective on exosome isolation-efforts for efficient exosome-based theranostics[J]. Theranostics, 2020, 10(8): 3684-3707.
[11] FAN C, LI Y, LAN T, et al.Microglia secrete miR-146a-5p-containing exosomes to regulate neurogenesis in depression[J]. Mol Ther, 2022, 30(3): 1300-1314.
[12] TABRIZI SJ, ESTEVEZ-FRAGA C, VAN ROON-MOM WMC, et al. Potential disease-modifying therapies for Huntington’s disease: lessons learned and future opportunities[J]. Lancet Neurol, 2022, 21(7): 645-658.
[13] KUMAR A, GUPTA V, SHARMA S, Donepezil[M]. Treasure Island (FL): StatPearls Publishing LLC, 2024.
[14] SALLOWAY SP, SEVINGY J, BUDUR K, et al.Advancing combination therapy for Alzheimer’s disease[J]. Alzheimer’s Dement (NY), 2020, 6(1): e12073.
[15] HAMPEL H, HARDY J, BLENNOW K, et al.The amyloid-β pathway in Alzheimer’s disease[J]. Mol Psychiatry, 2021, 26(10): 5481-5503.
[16] ZHANG H, WEI W, ZHAO M, et al.Interaction between Aβ and Tau in the pathogenesis of Alzheimer’s disease[J]. Int J Biol Sci, 2021, 17(9): 2181-2192.
[17] VOYTYUK I, DE STROOPER B, CHáVEZ-GUTIéRREZ L. Modulation of γ- and β-Secretases as early prevention against Alzheimer’s disease[J]. Biol Psychiatry, 2018, 83(4): 320-327.
[18] JACOBSEN H, OZMEN L, CARUSO A, et al.Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice[J]. J Neurosci, 2014, 34(35): 11621-11630.
[19] SEVIGNY J, CHIAO P, BUSSIèRE T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease[J]. Nature, 2016, 537(7618): 50-56.
[20] RAHMAN A, HOSSEN MA, CHOWDHURY MFI, et al.Aducanumab for the treatment of Alzheimer’s disease: a systematic review[J]. Psychogeriatrics, 2023, 23(3): 512-522.
[21] MINTUN MA, LO AC, DUGGAN EC, et al.Donanemab in early Alzheimer’s disease[J]. N Engl J Med, 2021, 384(18): 1691-1704.
[22] SCHIMRIGK S, MARZINIAK M, NEUBAUER C, et al.Dronabinol is a safe long-term treatment option for neuropathic pain patients[J]. Eur Neurol, 2017, 78(5-6): 320-329.
[23] MATTACE RG, RUSSO R, CALIGNANO A, et al.Palmitoylethanolamide in CNS health and disease[J]. Pharmacol Res, 2014, 86: 32-41.
[24] PETROSINO S, DI MARZO V.The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations[J]. Br J Pharmacol, 2017, 174(11): 1349-1365.
[25] BORTOLETTO R, BALESTRIERI M, BHATTACHARYYA S, et al.Is it time to test the antiseizure potential of palmitoylethanolamide in human studies? A systematic review of preclinical evidence[J]. Brain Sci, 2022, 12(1): 101.
[26] SCUTERI D, GUIDA F, BOCCELLA S, et al.Effects of palmitoylethanolamide (PEA) on nociceptive, musculoskeletal and neuropathic pain: systematic review and meta-analysis of clinical evidence[J]. Pharmaceutics, 2022, 14(8): 1672.
[27] ZHAO L, JING XJ, JIANG SJ.Treatment of Parkinson’s disease with selegiline combined with levodopa in 51 cases[J]. Anhui Medical and Pharmaceutical Journal(安徽医药), 2022, 26(2): 406-409.
[28] SI HT, REN HY, WANG XB, et al.Analysis of the effect of selegiline combined with levodopa in the treatment of Parkinson’s disease patients[J]. Clinical ＆ Medical Engineering(临床医学工程), 2024, 31(1): 23-24.
[29] JENNER P.Stalevo^® : a pioneering treatment for off periods in Parkinson’s disease[J]. Eur J Neurol, 2023, 30(Suppl 2): 3-8.
[30] MA LL, ZHANG L, WU YY.Clinical study of levodopa/carbidopa combined with entacarbine in the treatment of Parkinson’s disease[J]. Journal of Medical Forum(医药论坛杂志), 2022, 43(13): 49-52.
[31] ZHANG BB, HOU Y, LOU W.The therapeutic effect of pramipexole combined with dopamine hydrazine tablets in the treatment of Parkinson’s disease and its effect on serum BDNF 5-HT NE[J]. Hebei Medicine, 2018, 24(8): 1297-1301.
[32] LIU SM, MA N, NIU ZL, et al.The efficacy of pramipexole combined with doposazid tablets in the treatment of Parkinson’s disease patients[J]. Medical Journal of Chinese People’s Health(中国民康医学), 2024, 36(2): 9-11.
[33] DONNELLY CJ, GRIMA JC, SATTLER R.Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?[J]. Neurodegener Dis Manag, 2014, 4(6): 417-437.
[34] LIU J, WANG F.Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications[J]. Front Immunol, 2017, 8: 1005.
[35] NDAYISABA A, KAINDLSTORFER C, WENNING GK.Iron in neurodegeneration-cause or consequence?[J]. Front Neurosci, 2019, 13: 180.
[36] SHAN G, LI Y, ZHANG J, et al.A small molecule enhances RNA interference and promotes microRNA processing[J]. Nat Biotechnol, 2008, 26(8): 933-940.
[37] BADAL S, HER YF, MAHER LJ.Nonantibiotic effects of fluoroquinolones in mammalian cells[J]. J Biol Chem, 2015, 290(36): 22287-22297.
[38] CUDKOWICZ ME, SHEFNER JM, SCHOENFELD DA, et al.Trial of celecoxib in amyotrophic lateral sclerosis[J]. Ann Neurol, 2006, 60(1): 22-31.
[39] GOLDSHTEIN H, MUHIRE A, PETEL LV, et al.Efficacy of ciprofloxacin/celecoxib combination in zebrafish models of amyotrophic lateral sclerosis[J]. Ann Clin Transl Neurol, 2020, 7(10): 1883-1897.
[40] CHEN WY, BAILEY EC, MCCUNE SL, et al.Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase[J]. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94(11): 5798-5803.
[41] GUIBERSON NGL, PINEDA A, ABRAMOV D, et al.Mechanism-based rescue of Munc18-1 dysfunction in varied encephalopathies by chemical chaperones[J]. Nat Commun, 2018, 9(1): 3986.
[42] FELS JA, DASH J, LESLIE K, et al.Effects of the investigational drug sodium phenylbutyrate-TUDCA (AMX0035) on the transcriptional and metabolic landscape of sporadic ALS fibroblasts[J]. Ann Clin Transl Neurol, 2022, 9(10): 1551-1564.
[43] SUN Y, LI X, BEDLACK R.An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis[J]. Expert Rev Neurother, 2023, 23(1): 1-7.
[44] WANG X, SUN G, FENG T, et al.Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression[J]. Cell Research, 2019, 29(10): 787-803.
[45] LIU QQ, DING SK, SHANG YZ.Research progress in the treatment of neurodegenerative diseases with traditional Chinese medicine[J]. Journal of Chengde Medical University(承德医学院学报), 2021, 38(6): 518-521.

抗神经退行性疾病复方药物研究进展

Research progress in compound drugs for anti-neurodegenerative diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

[1]	申雪, 江海燕, 范潇予, 李万芳, 包捷, 何博赛, 靳洪涛. 联合用药治疗肝纤维化的研究概况与展望[J]. 中国药物警戒, 2024, 21(9): 985-990.
[2]	江海燕, 周甜雨, 范潇予, 李万芳, 包捷, 靳洪涛. 抗肿瘤复方药物研发现状与挑战[J]. 中国药物警戒, 2024, 21(9): 961-966.
[3]	徐帅, 张玲, 赵玉清, 杨一点, 卞昊宇, 张立平. 中药多靶点干预代谢综合征血管内皮损伤研究进展[J]. 中国药物警戒, 2023, 20(3): 353-359.
[4]	马一丹, 沈鑫, 杨珺, 闫加庆. NLRP3炎症小体在神经退行性疾病及其治疗中的作用研究进展[J]. 中国药物警戒, 2023, 20(11): 1316-1320.